This course has expired. View available courses.
Endocrinology
Uncommon but Manageable: Pancreatic Exocrine Insufficiency (PEI) (2019) – Mainpro+
The program will focus on identification of symptoms, signs and conditions that are associated with PEI, as well as the testing, diagnosis and treatment of PEI. PEI should be considered in the differential diagnosis of patients with unresolved GI complaints, particularly those with unexplained weight loss at higher risk of PEI (e.g., type I diabetes, heavy drinking/smoking, celiac disease, gastrointestinal resection). PEI and suspected PEI are treated with pancreatic enzyme replacement therapy (PERT) and lifestyle modifications.
DURATION
1 hr
PROFESSION
Physician
# OF CREDITS
1
ACCREDITATION
Mainpro+
EXPIRY DATE
2020-01-24
The program will focus on identification of symptoms, signs and conditions that are associated with PEI, as well as the testing, diagnosis and treatment of PEI. PEI should be considered in the differential diagnosis of patients with unresolved GI complaints, particularly those with unexplained weight loss at higher risk of PEI (e.g., type I diabetes, heavy drinking/smoking, celiac disease, gastrointestinal resection). PEI and suspected PEI are treated with pancreatic enzyme replacement therapy (PERT) and lifestyle modifications.
Faculty
Deanna Telner (MD, CCFP), Gabor Kandel (MD, FRCP), Jane Charters (BSc (PT), MD, MCFP), Peter J. Lin (MD, CCFP), Sol Stern (MD, MCFP)
Learning objectives
Au terme du programme, les participants pourront :
- Définir les caractéristiques et les prédicteurs du cancer du col de l’utérus.
- Décrire les tests de dépistage, y compris la cytologie (test Pap), la cytologie en milieu liquide et le dépistage conjoint (Pap/VPH).
- Expliquer l’importance du dépistage et l’importance du test du VPH pour le cancer du col de l’utérus chez les femmes de 30 ans ou plus à risque élevé de VPH (virus du papillome humain).
- Reconnaître les lignes directrices actuelles en matière de dépistage du VPH pour le cancer du col de l’utérus chez les femmes de 30 ans ou plus.
- Recommander des tests de dépistage au VPH pour procéder au triage de patientes de 30 ans ou plus.